

# GAME CHANGERS

## FOR BETTER AND AFFORDABLE MEDICINES FOR EUROPE

UNDER THE AUSPICES OF THE BULGARIAN MINISTRY OF HEALTH

08:45-09:15 REGISTRATION AND COFFEE

09:15-09:45 WELCOMING REMARKS

- Zlatmira Dobрева, Representative of the Ministry of Health, Bulgaria
- Andrzej Rys, Director Responsible for Health Systems, Medical Products and Innovation, Directorate-General for Health and Food Safety (DG SANTE), European Commission @EU\_Health

Introduction by Yannis Natsis, Policy Manager, Universal Access and Affordable Medicines, European Public Health Alliance (EPHA) @YNatsis

09:45-11:15 TRANSPARENCY IN PHARMACEUTICALS: DESIRABLE AND/OR FEASIBLE?

Open discussion moderated by Dr. Deborah Cohen, Investigations Editor, British Medical Journal (BMJ) @deb\_cohen

- Dr Andrew Hill, Senior Visiting Research Fellow, Department of Pharmacology and Therapeutics, Liverpool University
- Dr Síle Lane, Head, International Campaigns and Policy, Sense about Science, UK @Sile\_lane
- Francis Arickx, Head, Pharmaceutical Department, National Institute for Health and Disability Insurance (RIZIV INAMI), Belgium @INAMI\_RIZIV
- Aldo Golja, Senior Policy Advisor, Pricing and Reimbursement-Coordinator of the BeNeLuxA Initiative on Pharmaceutical Policy, Ministry of Health, Welfare and Sport, The Netherlands @MinVWS
- Boris Azais, Director, Public Policy for Europe and Canada, MSD @borisazais

11:15-11:30 COFFEE BREAK

11:30-13:00 DRUG DEVELOPMENT: DO THE INCENTIVES WORK?

Open discussion moderated by Dr. Deborah Cohen, Investigations Editor, British Medical Journal (BMJ)

- Dyfrig Hughes, Professor of Pharmacoeconomics, School of Healthcare Sciences, Bangor University, Co-Director, Centre for Health Economics & Medicines Evaluation @HughesDyfrig
- Els Torreele, Executive Director, Access Campaign, Médecins Sans Frontières (MSF) @ElsTorreele @MSF
- Elizabeth Kuiper, Executive Director Public Affairs European Federation of Pharmaceutical Industries and Associations, EFPIA @kuiper\_em @EFPIA
- Marcel Canoy, Advisor, Netherlands Authority for Consumers and Markets (ACM) @marcelcanoy

NOVEMBER 21, 2017

MARTIN'S BRUSSELS HOTEL

13:00-13:45 LUNCH

13:45-15:15 THE PUSH FOR ACCELERATED DRUG APPROVALS: SPEED AND DEREGULATION OVER PATIENT SAFETY AND ROBUST EVIDENCE?

Open discussion moderated by Dr. Deborah Cohen, Investigations Editor, British Medical Journal (R)

- Claudia Wild, Director, Ludwig Boltzmann Institute for Health Technology Assessment
- Antonio Addis, Researcher, Department of Epidemiology, Regional Health Service, Rome @AntonioAddis2
- Simon Collins, Patient Advocate, HIV i-Base @SimonCollins101
- Beate Wieseler, Head, Department of Drug Assessment, Institute for Quality and Efficiency in Health Care (IQWiG) @IQWiG
- Helen Lee, Unit B5 – Medicines: policy, authorisation and monitoring DG Santé, European Commission @EU\_Health

15:15-15:30 COFFEE BREAK

15:30-17:00 BUSINESS STRATEGIES, ANTICOMPETITIVE PRACTICES & MEDICINES' SHORTAGES: WHAT IS THE WAY OUT?

Open discussion moderated by Dr. Deborah Cohen, Investigations Editor, British Medical Journal (BMJ)

- Rainer Becker, Head of Unit for Antitrust Pharma and Health services, Directorate-General for Competition (DG COMP), European Commission @EU\_Competition
- Marc-Alexander Mahl, President, Medicines for Europe @medicinesforEU
- Aida Batista, Vice-President, European Association of Hospital Pharmacists (EAHP) @AidaBatista @EAHPtweet
- Fernando Lamata, Senior Expert on Health Care Policies, Impeller of the Association for a Fair Access to Medicines, Spain @LamataF
- Vlad Voiculescu, Member, Romanian Health Observatory @vlad\_voiculescu

17:00-18:00 NETWORKING RECEPTION